GEN-1

Shionogi & Co. plans to acquire Japan Tobacco's pharmaceutical subsidiaries Torii Pharmaceutical and Akros Pharma for ¥160 billion ($1.1 billion) to strengthen its global R&D capabilities.

Researchers are developing innovative non-viral delivery systems for IL-12 immunotherapy, targeting the tumor microenvironment while minimizing systemic toxicity in ovarian cancer treatment.

IMNN-101, a novel DNA-based COVID-19 vaccine, demonstrated a 2-4 fold increase in neutralizing antibody titers through Week 4 in Phase 1 trial participants.

GRIN Therapeutics' radiprodil receives FDA Breakthrough Therapy designation for treating seizures in patients with GRIN-related neurodevelopmental disorder, showing 86% median reduction in seizure frequency during Phase 1b trials.

PDS Biotech reaffirms the initiation of the VERSATILE-003 Phase 3 clinical trial in Q1 2025 for HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma.